Starpharma Gets US$3 Million From Astrazeneca Post The Successful Phase 1 Clinical Trial Of AZD0466

  • Feb 11, 2020 AEDT
  • Team Kalkine

Starpharma (ASX: SPL) has received USD 3 million from AstraZeneca after the successful dosing of the first patient in the phase 1 clinical trial of AZD0466 in December 2019.

The trial took place at several sites in the US & shall recruit patients diagnosed with a range of cancers.

At AEDT 1:13 PM, SPL shares are trading 1.293% above its previous close at $1.175.



All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK